ABT-751 (E7010)
Modify Date: 2025-08-22 16:58:12
ABT-751 (E7010) structure
|
Common Name | ABT-751 (E7010) | ||
|---|---|---|---|---|
| CAS Number | 141430-65-1 | Molecular Weight | 371.410 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 551.0±60.0 °C at 760 mmHg | |
| Molecular Formula | C18H17N3O4S | Melting Point | 162 °C(dec.) | |
| MSDS | N/A | Flash Point | 287.0±32.9 °C | |
Use of ABT-751 (E7010)ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 μM in neuroblastoma and non-neuroblastoma cell lines, respectively.IC50 Value: 1.5 μM(neuroblastoma); 3.4 μM(non-neuroblastoma)Target: Microtubule/Tubulinin vitro: ABT-751 shows the selective cytotoxicity with IC50 of 0.6–2.6 μM in neuroblastoma and 0.7–4.6 μM in other solid tumor cell lines. Furthermore, ABT-751 also exhibits a selective effect on dynamic microtubules and spares stable microtubules, accounting for the persistence of acetylated and detyrosinated α-tubulin positive polymerized tubules at the IC90 concentration of ABT-751. in vivo: In Calu-6 xenograft model, ABT-751 as a single agent at 100 and 75 mg/kg/day shows significant antitumor activity, while in combination with cisplatin, ABT-751 shows a dose-dependent enhancement in growth delay. In the HT-29 colon xenograft model, ABT-751 also shows significant antitumor activity as a single agent and produced a dose-dependent enhancement in growth delay In combination with 5-FU. In dogs with lymphoma, ABT-751 exhibits the dose-limiting toxicities that included vomiting, diarrhea, anorexia, or some combination of these with a maximum tolerated dose (MTD) of 350 mg/m2 PO q24h. Furthermore, the mean AUC and Cmax for ABT-751 at the MTD of 350 mg/m2 is 5.55 μg-hour/mL and 0.9 μg/mL, respectively. |
| Name | abt-751 |
|---|---|
| Synonym | More Synonyms |
| Description | ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 μM in neuroblastoma and non-neuroblastoma cell lines, respectively.IC50 Value: 1.5 μM(neuroblastoma); 3.4 μM(non-neuroblastoma)Target: Microtubule/Tubulinin vitro: ABT-751 shows the selective cytotoxicity with IC50 of 0.6–2.6 μM in neuroblastoma and 0.7–4.6 μM in other solid tumor cell lines. Furthermore, ABT-751 also exhibits a selective effect on dynamic microtubules and spares stable microtubules, accounting for the persistence of acetylated and detyrosinated α-tubulin positive polymerized tubules at the IC90 concentration of ABT-751. in vivo: In Calu-6 xenograft model, ABT-751 as a single agent at 100 and 75 mg/kg/day shows significant antitumor activity, while in combination with cisplatin, ABT-751 shows a dose-dependent enhancement in growth delay. In the HT-29 colon xenograft model, ABT-751 also shows significant antitumor activity as a single agent and produced a dose-dependent enhancement in growth delay In combination with 5-FU. In dogs with lymphoma, ABT-751 exhibits the dose-limiting toxicities that included vomiting, diarrhea, anorexia, or some combination of these with a maximum tolerated dose (MTD) of 350 mg/m2 PO q24h. Furthermore, the mean AUC and Cmax for ABT-751 at the MTD of 350 mg/m2 is 5.55 μg-hour/mL and 0.9 μg/mL, respectively. |
|---|---|
| Related Catalog | |
| References |
[5]. Gaynon PS, Harned TM; for the Therapeutic Advances in Childhood LeukemiaLymphoma (TACL) Consortium. |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 551.0±60.0 °C at 760 mmHg |
| Melting Point | 162 °C(dec.) |
| Molecular Formula | C18H17N3O4S |
| Molecular Weight | 371.410 |
| Flash Point | 287.0±32.9 °C |
| Exact Mass | 371.093964 |
| PSA | 108.93000 |
| LogP | 4.58 |
| Vapour Pressure | 0.0±1.5 mmHg at 25°C |
| Index of Refraction | 1.677 |
| RTECS | DB2734000 |
|---|
|
~%
ABT-751 (E7010) CAS#:141430-65-1 |
| Literature: Journal of Medicinal Chemistry, , vol. 35, # 13 p. 2496 - 2497 |
|
~%
ABT-751 (E7010) CAS#:141430-65-1 |
| Literature: Journal of Medicinal Chemistry, , vol. 35, # 13 p. 2496 - 2497 |
|
~%
ABT-751 (E7010) CAS#:141430-65-1 |
| Literature: Journal of Medicinal Chemistry, , vol. 35, # 13 p. 2496 - 2497 |
|
~%
ABT-751 (E7010) CAS#:141430-65-1 |
| Literature: Journal of Medicinal Chemistry, , vol. 35, # 13 p. 2496 - 2497 |
![4-[(3-aminopyridin-2-yl)amino]phenol structure](https://image.chemsrc.com/caspic/115/78750-68-2.png)
![Phenol, 4-[(3-nitro-2-pyridinyl)amino]- structure](https://image.chemsrc.com/caspic/391/78750-61-5.png)
| Tazac |
| Benzenesulfonamide, N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxy- |
| Galitidin |
| Distaxid |
| Zanizal |
| Calmaxid |
| N-{2-[(4-Hydroxyphenyl)amino]-3-pyridinyl}-4-methoxybenzenesulfonamide |
| nizatidine |
| Acinon |
| Nizax |
| Cronizat |
| Axid |
| E 7010 |